Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013
August 09, 2013 16:23 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was...
CaroTrans Bolsters Transpacific Service Network With New Philippines Agent Partnership
June 04, 2013 08:16 ET
|
CaroTrans
CLARK, NJ--(Marketwired - Jun 4, 2013) - CaroTrans, a leading global NVOCC (non-vessel operating common carrier) and ocean freight consolidator, today announces a strategic alliance with...
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
February 04, 2013 19:35 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the US Food and...
FDA Accepts Complete Response Submission Regarding the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
August 14, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed on July 31, 2012 with the U.S. Food and Drug Administration its complete...
Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
August 01, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed yesterday with the U.S. Food and Drug Administration its complete response to...
Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome
July 18, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion...
Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment
July 11, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") recently met with representatives of the U.S. Food and Drug Administration (the...
Innovative Med Concepts Debuts Revolutionary iPhone(R) App Designed to Monitor Daily Health Habits and Improve Well-Being
May 22, 2012 08:00 ET
|
Innovative Med Concepts, LLC
TUSCALOOSA, AL--(Marketwire - May 22, 2012) - Privately held Innovative Med Concepts, LLC today announced the availability of UShapeHealth, a new, user-friendly, mobile health application for the...
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
October 24, 2011 10:22 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 24, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, October 27, 2011 at 2:00...
Chronix Biomedical and Hemispherx Biopharma Jointly File Patent Application for a Blood Test for Chronic Fatigue Syndrome (CFS)
March 03, 2011 10:00 ET
|
Hemispherx Biopharma, Inc.
Chronix Technology Focuses on Changes to CFS Patients' DNA
Hemispherx and Chronix Plan Studies to Validate Technology as a Potential Diagnostic Test for CFS
SAN JOSE, Calif., March 3, 2011...